Aptargroup's biggest risks in the FY2024 10-K
- Manufacturing risks center on resin, rubber, metals, energy, transportation, labor disruptions, and reliance on some single-source materials.
- Pharmaceutical exposure includes customer-drug success, healthcare cost controls, royalty expirations, and prescription-market demand.
- Global operations add cybersecurity, geopolitical, tariff, regulatory, currency, climate, and customer-credit risks.
The risks most specific to Aptargroup
- Risks Related to Our Operations and Industry
Our ability to adequately source materials including those from a single supplier or from a single manufacturing location, could adversely impact our ability to deliver our products
Single-source resins and rubber components, or disruptions at suppliers and manufacturing locations, could prevent Aptar from delivering products.
- Risks Related to Our Operations and Industry
The success or failure of our customers’ products, particularly in the pharmaceutical market, may materially affect our operating results and financial condition
Pharmaceutical customers’ drug success or failure can materially change demand for Aptar’s dispensing systems after years of development work.
- Risks Related to Our Operations and Industry
Higher raw material costs and other inputs and an inability to offset these higher costs with price increases may materially adversely affect our operating results and financial condition
Volatility in plastic resin, rubber, metal, anodization, transportation, and energy costs may outpace Aptar’s pricing actions.
- Risks Related to Our Operations and Industry
If our integration of acquisitions or significant capital investments fail to generate expected returns, our financial performance may suffer
Failed integration of acquisitions, the Goldrain investment, or capacity expansions could prevent Aptar from achieving expected returns.
- Risks Related to Our Operations and Industry
Our internal information technology systems may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could disrupt our business or result in the loss of critical and confidential information
IT failures, data breaches, or declining local data-center availability could disrupt applications and force reliance on cloud solutions.
- Risks Related to Financial, Legal and Regulatory Matters
We have approximately $936.3 million in recorded goodwill at December 31, 2024, and changes in future business conditions could cause this asset to become impaired, requiring write-downs that would reduce our operating income
Aptar’s approximately $936.3 million of goodwill could require impairment charges if cash flows, market conditions, or discount rates worsen.
- Risks Related to Financial, Legal and Regulatory Matters
Government regulation on environmental matters, including recycling or environmental sustainability policies could impact our business
Environmental rules restricting materials or requiring recycling could force changes to suppliers, manufacturing processes, and product technologies.
- Risks Related to Financial, Legal and Regulatory Matters
Future government regulations of healthcare cost containment policies may impact our pharmaceutical sales
Government and insurer controls on drug prices and coverage could reduce pharmaceutical customers’ demand and pricing.
- Risks Related to Financial, Legal and Regulatory Matters
Our financial performance could be impacted by loss of royalty revenues
Expiration of customer contracts could eliminate royalty revenue from dispensing devices developed for particular drug formulations.
All 28 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Operations and Industry
- 01If there is deterioration in economic conditions, our business and operating results could be materially adversely impacted
- 02Geopolitical conditions, including trade disputes and acts of war or terrorism, could have a material adverse effect on our operations and financial results
- 03Significant tariffs or other restrictions imposed on foreign imports by the U.S. and related countermeasures taken by impacted foreign countries could have a material adverse effect on our operations and financial results
- 04Increased global cybersecurity threats and more sophisticated, targeted computer crime could pose a risk to our operations
- 05We face strong global competition and our market share could decline
- 06In difficult market conditions, our fixed costs structure combined with potentially lower revenues may negatively impact our results
- 07Our ability to adequately source materials including those from a single supplier or from a single manufacturing location, could adversely impact our ability to deliver our products
- 08Global health crises, such as the COVID-19 pandemic, have adversely affected our business, and future developments or other global pandemics could cause adverse effects, which may be material
- 09Consolidation of our customer base could impact our business
- 10The success or failure of our customers’ products, particularly in the pharmaceutical market, may materially affect our operating results and financial condition
- 11Our revenue and results of operations may suffer upon the bankruptcy, insolvency or other credit failure of our customers
- 12Higher raw material costs and other inputs and an inability to offset these higher costs with price increases may materially adversely affect our operating results and financial condition
- 13If disputes with our unions arise, or if our unionized workers engage in a strike or other work stoppage, or if our suppliers engage in a strike or other work stoppage, we could experience a significant disruption of operations
- 14We may not achieve the expected benefits from our restructuring initiatives, which could adversely affect our business and operations
- 15If our integration of acquisitions or significant capital investments fail to generate expected returns, our financial performance may suffer
- 16Our internal information technology systems may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could disrupt our business or result in the loss of critical and confidential information
Risks Related to Financial, Legal and Regulatory Matters
- 17We have foreign currency translation and transaction risks that may materially adversely affect our operating results
- 18We have approximately $936.3 million in recorded goodwill at December 31, 2024, and changes in future business conditions could cause this asset to become impaired, requiring write-downs that would reduce our operating income
- 19We are subject to a variety of laws and regulations and changes in, or failure to comply with, these laws or regulations could have an adverse impact on the Company’s reputation, business and results of operations
- 20We are exposed to risks from lawsuits and claims, including product liability claims, as well as investigations, audits and other proceedings, which may result in substantial costs and expenses or interruption of our normal business operations
- 21Challenges to, or the loss of, our intellectual property rights could have an adverse impact on our ability to compete effectively
- 22Government regulation on environmental matters, including recycling or environmental sustainability policies could impact our business
- 23Future government regulations of healthcare cost containment policies may impact our pharmaceutical sales
- 24Interest rate volatility could increase our borrowing costs
- 25We could be subject to changes in tax rates, the adoption of new tax legislation or rules or exposure to additional tax liabilities
- 26Our financial performance could be impacted by loss of royalty revenues
General Risk Factors
- 27Global climate change and legal, regulatory, or market measures to address climate change, may negatively affect our business, operations and financial results
- 28Ownership by Certain Significant Stockholders
Other Aptargroup 10-Ks
- FY2025 10-K risk factors27 risks2 new3 dropped10 reworded
Manufacturing-site disruptions are newly highlighted as a direct threat to production, deliveries, launches, and customer relationships.
Filed Feb 06, 2026
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.